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Resumo 
 
O melanoma maligno é considerado a forma mais letal de cancro de pele, com uma elevada 
tendência para metastizar para o cérebro. Atualmente, as metástases cerebrais são tratadas 
através de cirurgia, quimioterapia, radioterapia e radiocirurgia, mas o sucesso destes 
tratamentos são mínimos, como tal novas estratégias terapêuticas são importantes e 
necessárias. 
A fim de determinar novas estratégias de terapia cancerígena, são precisos modelos animais 
adequados para investigar os efeitos dos tratamentos. Em trabalhos anteriores, desenvolveu-se 
um novo modelo animal, através de injecção, na corrente sanguínea de organismos 
imunodeficientes (nod/scid), de células de melanoma humano . Estes animais 
imunodeficientes, para além de desenvolver tumores cerebrais, também desenvolveram 
metástases em outros órgãos. A partir dos tumores desenvolvidos, foi determinada, por 
sequenciamento de RNA, uma lista de genes candidatos responsáveis pelas metástases 
cerebrais,. Com uma análise bioinformática, utilizando o connectivity map (cMAP), foi 
possível encontrar várias drogas, administradas em pacientes para outros fins terapêuticos, 
que podem ser também eficazes no tratamento de metástases cerebrais. 
O objetivo deste trabalho foi testar os fármacos candidatos, determinados pelas sequencias de 
RNA, em quatro linhas celulares diferentes de melanoma humano. Dos ensaios in vitro 
realizados com 9 drogas candidatas, apenas 5 mostraram ter algum potencial, mas só 3 foram 
selecionadas (Tricostatina A, Metildopa e Pentamidina) para serem testadas in vivo. Esta 
seleção baseou-se na análise do peso molecular, devido às limitações da passagem pela 
barreira hematoencefálica. 
Nos resultados in vivo, observou-se um efeito positivo, ainda que transitório, sobre a carga 
tumoral e o volume do tumor após quatro semanas de tratamento, quando eram expostos com 
metildopa. Assim, estudos adicionais têm de ser realizados utilizando a metildopa, para se 
confirmar e validar os resultados obtidos, e perceber  se é suficientemente eficaz para ser 
utilizada de forma preventiva.  
Com este trabalho também foi possível otimizar-se protocolos de ressonância magnética para 
facilitar a observação dos tumores, especialmente os de menores dimensões. Para além disso, 
a ressonância magnética também permite verificar se os tumores estão a invadir tecidos 
circundantes. Este protocolo tornou-se uma boa ferramenta que pode ser usado em futuros 
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estudos, permitindo estudar de forma mais eficaz as alterações dos tumores, e contribuir assim 
para o desenvolvimento de melhores tratamentos. 
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Abstract 
 
Malignant melanoma is the most lethal form of skin cancer, with a high propensity to 
metastasize to the brain. Melanoma brain metastases are currently treated with surgery, 
chemotherapy, radiotherapy and radiosurgery. Positive treatment results are, however 
minimal, and new therapeutic strategies are therefore needed. 
In order to determine new treatment strategies, suitable animal models to study effects of 
treatment are crucial. In previous work done in the group, a novel animal model was 
developed, by injecting human melanoma brain metastasis cell lines into the blood stream of 
immunodeficient (nod/scid) mice, with subsequent metastasis to the animal organs. From 
these tumors, a candidate gene list responsible for melanoma brain metastasis was determined 
by RNA sequencing. Subsequent bioinformatics analysis using Connectivity Map was used to 
find several drugs already used on patients for other purposes than cancer, which may also be 
effective in the treatment of melanoma brain metastasis.  
The aim of this work was to test the identified potential new drug candidates, on melanoma 
metastatic cell lines. In the first part of the work, in vitro assays were performed to investigate 
the potential effects of nine of the drug candidates on four different human melanoma 
metastatic cell lines. From these 9 candidates 5 showed potential and three were selected for 
in vivo studies (Trichostatin A, Methyldopa and Pentamidine). Only these were selected due 
to molecular weight and limitations of the blood brain barrier. 
In vivo results showed a transient positive effect on tumor burden and volume around week 4 
when treated with Methyldopa. Further studies need to be performed utilizing this drug to 
verify its capacity when applied as a preventive form of treatment. With this work MRI 
protocols have been optimized allowing easier detection of the tumors, in particular the 
smaller ones. In addition it is also possible to verify whether the tumors are leaky or not. This 
can then be used in future animal studies, to see whether leakiness changes as a function of 
treatment. 
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1) Introduction: 
 
1.1) Principles of Cancer 
 
In 2012, the worldwide burden of cancer rose to an estimated 14 million new cases per 
year, a figure expected to rise to 22 million annually within the next two decades. Over the 
same period, cancer deaths are predicted to rise from an estimated 8.2 million annually to 13 
million per year. Globally, in 2012 the most common cancers diagnosed were those of the 
lung (1.8 million cases, 13.0% of the total), breast (1.7 million, 11.9%), and large bowel (1.4 
million, 9.7%). The most common causes of cancer death were cancers of the lung (1.6 
million, 19.4% of the total), liver (0.8 million, 9.1%), and stomach (0.7 million, 8.8%) (1).  
Cancer cells are unlike most cells in the human body, which only divide when 
exposed to extracellular signals such as growth factors.  Instead, cancer cells divide more or 
less continuously, ultimately forming tumors. By the time the tumor can be felt or found using 
current technologies, it already contains millions of cells. Tumors can be benign or malignant. 
The most fearsome characteristic of cancer cells is their ability to invade surrounding 
tissues and spreading to other parts of the body using the circulatory and lymphatic system. 
When malignant cells become lodged in a distant part of the body, they divide and grow 
forming a new tumor at that new site. This process is called metastasis, (explained in more 
detail ahead); this often results in organ failures and makes cancer treatment very complicated 
(2).  
Cancer has specific traits that are important to comprehend, as to fully understand the 
capacities of this disease and therefore be able to give a more generalized form of treatment. 
These traits are known as the “hallmarks of cancer” and are described below: 
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Figure. 1.1 – illustration of the hallmarks of cancer, adapted from (3). 
 
• Sustaining proliferative signaling 
 
Normal cells require external growth signals to proliferate, and these signals are 
transmitted through receptors that pass through the cell membrane. In contrast, cancer cells 
can grow and divide without external growth signals. Some cancer cells are autosufficent, 
generating their own growth factor molecules. Receptors themselves can be overexpressed. 
Or mutated ones can send signals without any growth factors at all (3). 
 
 
• Evading growth suppressors 
 
Cancer cells are generally resistant to growth-preventing signals from the neighbouring 
normal cells. The growth of normal cells is kept under control by growth inhibitors in the 
surrounding environment, in the extracellular matrix and on the surfaces of neighboring cells. 
These inhibitors act on the cell cycle clock, by interrupting cell division (mitosis) in the 
interphase. 
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Ultimately, the growth inhibitor signals are funneled through the downstream 
retinoblastoma protein (pRB), which prevents the inappropriate transition from (G1) to S. If 
pRB is damaged through a mutation in its gene, or by interference from human papilloma 
virus, the cell can divide uncontrollably (3). 
 
 
• Avoiding immune destruction 
 
By disrupting the processes of the cancer immunity cycle throughout the body, tumors can 
avoid detection by the immune system and limit the extent of immune destruction. Some 
processes by which tumor cells avoid immune destruction is by disrupting antigen detection, 
inhibiting T-cell activation by dendritic cells, blocking T-cell infiltration into tumor and 
suppressing cytotoxic T-cell activity (3, 4, 5). 
 
• Enabling replicative immortality 
 
Non-cancer cells die after a certain number of divisions or go into quiescence. Some types 
of cells, such as nerve and heart muscle cells, become quiescent when they reach maturity but 
continue to perform their main functions for the rest of the organism's life. Multinucleated 
muscle cells that do not undergo cytokinesis are also often considered to be in the G0 stage. 
Cancer cells escape this limit and are apparently capable of indefinite growth and division, 
becoming immortal. But those immortal cells have damaged chromosomes, and can become 
cancerous. 
Mammalian cells have an intrinsic program, the Hayflick limit, that limits their multiplication 
to about 60–70 doublings, at which point they reach a stage of senescence. This limit can be 
overcome by disabling their pRB and p53 tumor suppressor proteins, which allows them to 
continue.  
The counting device for cell doublings is the telomere, which loses DNA at the tips of every 
chromosome during each cell cycle. Many cancers involve the upregulation of telomerase, the 
enzyme that maintains telomeres length (3). 
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• Activating invasion & metastasis 
 
Initiation of metastasis requires invasion, which is enabled by EMT (Epithelial – 
Mesenchymal Transition) (Figure. 1.2). Carcinoma cells in primary tumors lose cell-cell 
adhesion mediated by E-cadherin repression and break through the basement membrane with 
increased invasive properties, and enter the bloodstream through intravasation. Later, when 
these circulating tumor cells (CTCs) exit the bloodstream to form micrometastases, they 
undergo MET (Mesenchymal – Epithelial Transition) for clonal outgrowth at these metastatic 
sites. Thus, EMT and MET form the initiation and completion of the invasion-metastasis 
cascade. 
 A partial loss of E-cadherin, the caretaker of the epithelial state, is associated with 
carcinoma progression (6). During EMT, E-cadherin gene transcriptional repression, promoter 
methylation, and protein phosphorylation and degradation have all been observed (7, 8). In 
order to invade through local basement membrane (surrounding the tumor or the tumors 
vasculature), these mesenchymal tumor cells up-regulate several secreted (MMPs) and 
membrane-tethered (MT-MMPs) proteases to break down ECM components (3). 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1.2 - EMT in local invasion 
and intravasation. Activation of the 
EMT program is mostly characterized by  
loss of E-cadherin expression. In order to 
invade through local basement 
membrane, these mesenchymal tumor 
cells up-regulate several secreted 
(MMPs) and membrane-tethered (MT-
MMPs) proteases to break down ECM 
components. Adapted from (9) 
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• Tumor promoting inflammation 
 
The tumor microenvironment is often infiltrated by innate and adaptive immune system 
cells, which enable tumors to mimic inflammatory conditions seen in normal tissues. This will 
promote tumor progression by supplying the tumor microenvironment with growth factors, 
survival factors, pro-angiogenic factors, extracellular matrix (ECM) – modifying enzymes 
that promote angiogenesis, invasion, and metastasis and also inductive signals that activate 
epithelial-mesenchymal transition (EMT) (3). 
 
• Inducing angiogenesis 
 
 Angiogenesis is the process by which new blood vessels are formed. Cancer cells 
appear to be able to kickstart this process, ensuring that such cells receive a continual supply 
of oxygen and other nutrients. 
 Cancer cells initially lack angiogenic ability, limiting their ability to expand. In order 
to progress, they must develop a blood supply. Inducers and inhibitors balance angiogenesis. 
Inducers include vascular endothelial growth factor (VEGF) and acidic and basic fibroblast 
growth factor (FGF 1/2), which bind to transmembrane tyrosine kinase receptors displayed on 
endothelial cells. An inhibitor is thrombospondin-1, which binds to CD36. Thrombospondin-1 
is regulated by p53, so loss of p53 can promote angiogenesis. 
Angiogenesis is involved in the growth of all tumors, but most pronounced in cervix, breast 
and melanoma tumors (3). 
 
 
• Genome instability & mutation 
 
Multiple alterations in the genomes of cancer cells serve as the foundation for many 
oncogenic processes. Cancer cells take advantage of increased rates of mutations in order to 
accumulate several mutations needed to foster carcinogenesis. They do this through increased 
sensitivity to mutagenic agents and/or a breakdown in one or more of the cell’s DNA repair 
mechanisms mediated by genes such as p53 or breast cancer type 1 susceptibility protein 
(BRCA1). Also when caretaker genes are inactivated or suppressed, tumor cells can increase 
the rate of mutations and, subsequently, tumorigenesis (3, 10).  
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• Resisting cell death 
 
Apoptosis is a form of programmed cell death (cell suicide), the mechanism by which 
cells are programmed to die in the event they become damaged.  
Apoptosis can be triggered by an overexpressed oncogene, and this may be the primary means 
by which such mutant cells are continually removed. Conversely, cancer cells must overcome 
apoptosis to progress. 
The apoptotic machinery can be divided into sensors, which monitor the cell for 
abnormal behavior, and effectors, which cause apoptosis. The sensors include survival signals 
and their receptors, which monitor the cell for DNA damage, oncogene overexpression, and 
low oxygen (hypoxia). They monitor survival signals from the cell matrix and neighboring 
cells. 
Sensors include IGF-1/IGF2 and their receptor IGF-1R; and IL-3 and its receptor. The 
effectors include FAS ligand and its receptor, and TNF-α and its receptor. The p53 tumor 
suppressor protein elicits apoptosis in response to DNA damage, and is a major mechanism of 
cancer control. In order for cancer to progress, it must overcome p53, and in fact, p53 is 
mutated in half of all cancers (3). 
 
 
• Deregulation of cellular energetics 
 
To sustain uncontrolled proliferation, cancer cells make adjustments to their energy 
production by reprogramming their glucose metabolism, upregulating glucose transporters 
such as glucose transporter 1 (GLUT1) and depending on alternate metabolic pathways. 
Although limiting energy production to the glycolysis phase decreases the amount of 
adenosine triphosphate (ATP) produced, it also allows cancer cells to divert glycolic 
intermediates to various pathways, including those required to assemble new cells (3). 
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1.2) The Cell Cycle 
 
The cell cycle is controlled by specific checkpoints, which stop the cells from progressing 
to next phase or completing the current one. These checkpoints ensure completeness of the 
genome and that the stage of the cell cycle is properly completed before the next phase is 
begun. The S phase, which concerns DNA replication, is followed by the M phase or mitosis, 
which involves chromosome segregation, and the cycle is continued by cell division. There 
are three internal checkpoints that evaluate the eukaryotic cell cycle:  
• G1/S: cells check whether they should continue through division or enter a resting 
stage and whether their genome is able to divide. 
• G2/M boundary: cells check whether their DNA is fully replicated and undamaged 
before progression into the M phase. If not, the cell cycle is arrested in the S-G2 by 
inactivation of Cdc25 and activation of Wee1.  
• Metaphase/anaphase: cells check whether all chromosomes are attached to the bipolar 
mitotic spindle via their kinetochores and whether the sister chromatids are ready for 
separating from each other (11). 
 
 
 
 
 
 
 
Figure.1.3 – The cell cycle. The cell 
grows continuously in interphase, which 
consists of three phases: DNA replication 
is confined to S phase; G1 is the gap 
between M phase and S phase, while G2 
is the gap between S phase and M phase. 
In M phase, the nucleus and then the 
cytoplasm divide. Some cells become 
quiescent when they reach maturity and 
do not undergo cytokinesis are also often 
considered to be in the G0 stage, image 
from (12). 
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Checkpoints are meant to stop the cell cycle when genome integrity is damaged. 
Hence cells with genetic mutations are prevented from further division, and transition of the 
fault into subsequent cell generations is prevented. Cells with damaged DNA become arrested 
in these checkpoints. Arrest in G1 prevents copying of damaged bases and arrest in G2 allows 
cells to repair DNA double-strand breaks.  
The cell cycle and its checkpoints are working properly and perfectly in a healthy body. 
However sometimes some random stimuli like genetic mutations or UV light disturb the 
natural balance and can induce repression of tumor suppressor genes or overexpression of 
oncogenes, thus leading to tumor development (13). 
 
 
1.3) Melanoma 
 
Malignant melanoma is the ninth most common cancer in Europe and the 19th most 
common cancer worldwide, with around 232,000 new cases diagnosed in 2012 (14, 15). 
The main known risk factor for melanoma is sunlight exposure. Other risk factors that can 
increase the incidence of melanoma are ultraviolet radiation, skin and hair type as well as eye 
color, family history (hereditary mutation), previous cancer (metastasis) and radiotherapy, as 
well as a weakened immune system (16). 
Melanomas most often arise within epidermal melanocytes of the skin, although they 
can also originate from melanocytes such as those lining the choroidal layer of the eye, gastro 
intestine & genitourinary system mucosal surfaces, or the meninges. Melanoma is also among 
the most common cancer to metastasize due to its invasive properties. Clinical staging for 
primary cutaneous melanoma employs measurements of thickness (in millimeters), presence 
of ulceration, penetration through cutaneous layers, mitotic rate, evidence of “in transit” 
metastasis, tumor spread to draining lymph nodes, and evidence of distant metastasis. 
Management issues in melanoma can be classified in terms of prevention, diagnosis, local 
disease management, and treatment of metastatic disease (17). 
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1.4) Brain Metastasis 
 
Brain metastasis is the leading neoplastic disease in the human central nervous system 
(CNS) (18). It usually ascertains itself at the end stage of the disease's advancement and 
causes a sharp deterioration in patients' life quality (19). The period of latency differs 
depending on the tumors origin. Formation of brain metastasis is a common outcome for 40% 
to 60% of melanoma patients (20, 21, 22) 
 
In general, brain metastatic tumors are resistant to chemotherapy and even some newly 
emerged targeted therapeutic regimens. The blood-brain barrier (BBB) is known as the major 
obstacle for delivering drugs to the site of tumor cells inside the brain, due to low drug 
penetration (18). Therapeutic approaches are being selected based on the type of primary 
cancer, the number and location of the metastatic lesions as well as the stage of cancer. 
Current standard treatment for patients with brain metastasis is surgical resection followed by 
radiotherapy, and sometimes chemotherapy. These treatments may decrease the chance of 
recurrences of brain metastasis, and can increase the patient's quality of life (23). Precise 
considerations must be applied before choosing a proper treatment. A convenient selection of 
pharmacological agents can help patients with certain hindering symptoms. However, an 
unjustified choice of treatment could lead to a reduction in the patient's quality of life. In 
general, the life expectancy for patients with brain metastasis is poor, around 6 months 
regardless of treatment (22). 
 
1.5) Current Treatments 
 
Nowadays treatment for brain metastasis relies mainly on surgery, radiotherapy, 
chemotherapeutic agents or a combination of these. Due to the poor prognosis and lack of 
uniform approaches to therapy and assessments, patients with brain metastases have also been 
routinely excluded from clinical trials of new agents and were also thought unlikely to benefit 
from immunotherapy, in part because of the immunosuppressive effects of 
glucocorticosteroids. Standard radiotherapy approaches include stereotactic radiosurgery 
(SRS) or whole-brain radiotherapy (WBRT) (24). SRS, a precise focusing of radiation 
(Cyberknife and Gamma Knife) on well-defined individual intracranial lesions, is used just on 
a few well circumscribed metastatic lesions from melanoma brain metastases, barring issues 
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that warrant urgent surgery such as hemorrhage or mass effect and remains the standard of 
care (25) SRS without WBRT may also be a viable option in patients with one or few 
metastases and contraindications for surgery. WBRT, in contrast, involves irradiation of the 
entire brain with a uniform dose. SRS and WBRT are both used as primary or adjuvant 
therapies in patients with melanoma and brain metastases; notably, however, comparisons of 
surgical resection followed by WBRT and WBRT alone in these patients have not yielded 
definitive results (26).  
Chemotherapy alone is generally ineffective for the treatment of melanoma CNS 
metastases. Failure of systemic treatment for brain metastases in the past has been blamed on 
the inability of most experimental agents to pass the blood–brain barrier in addition to the low 
activity of these agents against melanoma (18, 27). 
Until recently, no compounds have demonstrated a significant survival benefit for 
patients with melanoma who develop brain metastases, and the prognosis for these patients 
has remained poor.  
 
 
1.6) Blood Brain Barrier and Drug Delivery 
 
Circulating tumor cells that reach the brain must pass through the BBB in order to form 
metastatic colonies in the brains parenchyma. Previous studies have demonstrated that 
endothelial cells lining the blood vessels in the brain are distinct from the endothelial cells in 
other organs (28). There are tight junctions between the endothelial cells that cover the 
internal walls of the vessels, forming a continuous sheath, which inhibits free, transcapillary 
movement of polar molecules. In addition, astrocytic endfeet and pericytes make up a 
continuous outer layer, further restricting access to the brain. Additionally, efflux transport 
proteins localized on the endothelium further diminish the effectiveness of circulating drugs 
by pumping them back to the blood circulation (29). Besides being a primary barrier for 
cancer cells, endothelial cells also play an important role in supporting the development of 
brain metastasis (30). 
 
The unique anatomy of the BBB provides a cellular barrier between the circulating 
blood and the interstitial fluid (31). It is also important for the homeostatic regulation of the 
brain and CNS functions (32). Tome Teese, Morris Karnovsky, and Milton Brightman 
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demonstrated the role of the BBB for the first time in the 1960s. By using electron 
microscopy, they showed is the presence of a barrier that prevents passage of injected 
electron-dense agents such as lanthanum salts. The BBB also works as a detoxification layer 
in the brain by assisting in removal of xenobiotics compounds from the brain.  
 
Any substances that are trying to reach the brain need to pass through the endothelial 
cell membranes. However, hydrophilic molecules such as glucose and amino acids, which 
supply the extensive metabolic needs of the brain, may overcome the lipophilic constrain. The 
fact that glucose easily pass through the BBB can be considered as proof for the presence of 
more complicated regulatory systems (33). The main pathway for hydrophobic substances to 
reach the brain is transcellular diffusion with the help of specialized proteins like solute 
carrier family (SLC), which has been shown to be effective in the flow of organic compounds, 
especially organic anions, through the BBB (34, 35). Other methods of transportation through 
BBB are achieved by energy dependent, active transporters, for instance the adenosine 
triphosphate (ATP)-binding cassette (ABC) family, which is mostly present at the luminal 
side of the BBB (36).  
In general, substances with a molecular weight above 500 Da are usually not able to 
penetrate the BBB. However, the complexity of the BBB means that charge, lipophilicity, 
binding to plasma proteins, and size of a molecule all must be taken into account when 
determining permeability of a drug through the BBB (37). Previous studies have shown that 
there was no efficient penetration of several hydrophobic molecules within the preferable 
range of molecular weight (38). 
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2) Material and methods 
 
2.1) Establishing Animal Models 
 
Many existing animal models for modelling cancer metastasis are murine derived, and 
thus likely do not reflect the same genetic and epigenetic changes as found in human cancers. 
Several models have also been derived, using orthotopic xenografts. However, these models 
show a rare incidence of brain metastasis, making them sub-optimal in brain metastatic 
research. Therefore, Prof. Thorsens research group has developed novel model systems, 
where human brain metastasis tumor cell lines from melanoma, lung adenocarcinomas or 
human breast cancers are injected systemically into nod/scid mice. The cell lines were 
injected into the left cardiac ventricle in mice, and tumor development was studied by 
bioluminescent imaging (BLI). During 3-6 weeks, all animals developed new tumors with a 
clear preference to the brain. T1 and T2 weighted (T1w and T2w) MRI showed multiple 
metastases within the brain, similar to what is seen in patients, and histology confirmed these 
findings. The models are thus among the very few which, in a systematic and consistent 
manner, can mimic the metastatic spread of cancers seen in patients. These models 
recapitulate most of the steps of the metastatic cascade, and thus provide a better tool to 
obtain information on the molecular mechanisms behind brain tumor metastasis. 
 
 
2.2) cMAP and drug selection 
  
After intracardiac injections, tumor burden was seen mainly in the animal brains, and 
to some extent in bone, adrenals and ovaries. These organs were removed after sacrificing the 
animals, the organs were dissociated, and tumor cells were sorted out by FACS. 
Transcriptome profiling with RNA-sequencing was performed on triplicate tumor samples 
from each organ, on a Illumina HiSeq 2000 platform (at BGI@UC Davis, Sacramento, CA).  
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2.3 Drugs 
 
The task in my Master work was to screen 9 out of the 10 remaining drugs for in vitro and in 
vivo treatment efficacy. These drugs are listed in the table below. 
 
 
Table. 2.1 - Table containing list of compounds. Also present here are all details relative to 
molecular weigh, dose usually administered, cMAP score and main applications of these drugs. 
 
Compound 
MW 
[Da] 
Dose 
[µM] 
cMAP 
Score Medical conditions where the drug is used 
Decamethonium 
Bromide 
418,2
9 10 -0,871 
Interrupts transmission at the skeletal 
neuromuscular junction by causing sustained 
depolarization of the motor end plate, skeletal 
muscle relaxation. 
Sulfapyridine 249,29 16 -0,872 A sulfanomide antibacterial.  
Pentamidine 340,42 7 -0,873 
Antimicrobial medication for prevention and 
treatment of pneumocystis pneumonia. Also 
used as prophylactic against PCP in patients 
receiving chemotherapy. 
Lymecycline 602,63 7 -0,878 A tetracycline broad-spectrum antibiotic. 
Fluticasone 444,51 8 -0,88 
Fluticasone propionate is a corticosteroid 
derived from fluticasone used to treat asthma 
and allergic rhinitis. It is also used to treat 
eosinophilic esophagitis. 
Lanatoside C 985,12 4 -0,882 
A cardiac glycoside, a type of drug that can 
be used in the treatment of congestive heart 
failure and cardiac arrhythmia (irregular 
heartbeat). 
Trichostatin A 302,37 1 -0,887 
An antifungal antibiotic and selectively 
inhibits the class I and II mammalian histone 
deacetylase. TSA has some potential as an 
anti-cancer drug. 
Methyldopa 275,73 15 -0,904 
Reduces high blood pressure 
(antihypertensive). 
Gabexate 311,37 19 -0,912 
A serine protease inhibitor used (as Gabexate 
Mesylate) in the treatment of pancreatitis, 
intravascular coagulation, and as a 
anticoagulant for haemodialysis. 
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2.4) Cell Culturing Techniques 
 
 2.4.1) Cell culturing 
 
The cell culture work was performed under sterile conditions inside a laminar airflow 
hood. All the working surfaces and equipment were disinfected with 70% ethanol prior to 
working and when finished. The cells were kept in incubation flasks and multi-well dishes, 
which were put in the incubator at 37ºC, 5% CO2 and 100% relative humidity. Solutions and 
disposables frequently used for cell culture are listed below. 
 
Table. 2.2 - Components comprising cell culture medium and freezing solution. 
Chemical  Supplier 
ALT DMEM 
   Dulbeccos Modified Eagles Medium 
   Heat inactivated fetal calf serum (FSC) 
   L-Glutamine, 200nM 
   Penicillin/Streptomycin (PEN-STREP), 100uL/mL 
   Non essential amino acids 100x 
   Plasmocin, 25mg/mL 
 
450mL 
50mL 
10mL 
10mL 
16mL 
0.1mL 
 
Sigma-Aldrich Inc. MO, USA 
Fischer Scientific, MA, USA 
BioWhittaker, Verviers, Belgium 
BioWhittaker, Verviers, Belgium 
BioWhittaker, Verviers, Belgium 
Invivogen, CA, USA 
Dulbeccos phosphate-buffered saline (PBS)  Sigma-Aldrich Inc. 
Trypsin EDTA, 0.25%  BioWhittaker 
Freezing solution1: 
   ALT DMEM 
   FCS (Fetal calf serum) 
 
9mL 
1mL 
 
Freezing solution 2: 
   1×PBS 
   Dimethyl sulphoxide (DMSO) 
 
8mL 
2mL 
 
Disposable pipettes: 5, 10, and 25mL   Sigma-Aldrich Inc 
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 The cells were grown in growth medium supplemented with 10% heat-inactivated 
newborn calf serum, four times the prescribed concentration of non-essential amino acids, 2% 
L-glutamine, penicillin (100 IU/ml), and streptomycin (100 µl/ml) (hereafter called ALT 
DMEM). The growth medium was exchanged twice a week. The cells were kept in medium 
sized blue filtered cap culture flasks (Nunc AS, Roskilde, Denmark) between experiments. 
The cells were regularly passaged when they reached 70-80% confluency. The old growth 
medium was removed, and the cells were washed with 3mL PBS. The PBS was then 
removed, and 3mL trypsin was added into the flask. After 3-4 minutes (when the cells were 
detached from the plastic surface) 4mL ALT DMEM was added in order to neutralize the 
effects of the trypsin. One third of the cell solution was then transferred to a new growth 
flask, and 25mL ALT DMEM was added.  
 
  2.4.2) Cell counting 
 
It was important to add the correct amount of tumor cells into each well of the dishes, 
when performing the proliferation assays. Thus, each experiment started by counting the 
number of cells in the culture flasks. The large sized flasks containing the cells were 
trypsinized with 4mL trypsin, followed by adding 5mL ALT DMEM into the culture flask. 
The cell solution was then transferred into sterile conical centrifuge 15mL tubes (Nunc, 
Thermo Scientific, NY, USA). We then determined the cell concentration using a Countess ® 
Automated cell counter (Life Technologies, NY, US) based on the manufactures instructions: 
10µl of cell solution were mixed with 10µl of Trypan blue (Life Technologies, NY, US) to 
exclude dead cells and thereafter pipetted into the Countess ® chamber slides. The chamber 
slide was placed into the cell counter, and the focus was adjusted to obtain a clear image of 
the cells. By pushing the "START" button on the machine the number of cells within the slide 
was automatically calculated and the cell counter showed the number of live cells, dead cells 
as well as the total number of cells, on the display. Each cell counting experiment was 
performed in duplicate. 
 
 
 
 
 
	  	  
	  16	  
  2.4.3) Freezing Cells 
 
All cell lines were used only for 12-15 passages before discarded, in order to minimize 
any potential, phenotypic drift of the cells. Thus, several samples of each cell line were frozen 
in liquid nitrogen, to ensure that we always had access to new and viable batches. 
The cells were first checked using the in-lab light microscope (TMS, Nikon 
Instruments Inc., NY, USA), to verify whether healthy and adequate in number. The cells 
were trypsinized, ALT DMEM was added, and the cell solution was transferred into 15mL 
tubes. The cells were then centrifuged at 900rpm for 4 minutes, and the growth medium was 
removed from the cell pellet. The freezing solution was then gently added into the tube, the 
cells were re-suspended, and 1mL of cell solution was transferred into each of 1.5mL 
cryotubes (Thermo Scientific Inc., MA, USA). The freezing solution was a mix of 2 different 
solutions, as described in Table 2.2. The vials were wrapped in tissue and placed in a freezer 
at -80º C over one night, in order to let them cool down slowly. Then they were transformed 
to the nitrogen liquid tank for long-term storage. 
 
2.5) Cell Lines 
 
Four melanoma metastasis low passage culture cell lines (Melmet1 pGF1, Melmet5 
pGF1, H1_DL2 and H3) were used in these experiments. Written consents were obtained 
from the patients before tumor material was collected. The Regional Ethical Committee (REC 
Number 013.09) and the Norwegian Directorate of Health (NSD Number 9634) approved the 
tissue collection and biobank storage of tumor biopsies and derived cell lines.  
The H1 and H3 cell lines were previously established in Prof. Thorsens lab, from 
melanoma brain metastasis of admitted patients at the Haukeland University Hospital, 
Bergen, Norway. The H1 cells were transduced with two lentiviral vectors, encoding Dendra 
(a green fluorescent protein (GFP) variant) and luciferase to obtain the H1_DL2 cell line.  
The Melmet1 and Melmet5 cell lines were a generous gift from Professor Øystein 
Fodstad (Dept. of Tumor Biology, the Norwegian Radium Hospital, Oslo, Norway)(5). 
Melmet1 was established from subcutaneous metastases of a 36-year-old female melanoma 
patient. This particular cell line have demonstrated invasive potential but low intrinsic 
proliferation in comparison to Melmet5 which shows a larger proliferation capacity. Melmet5 
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was established from a lymph node metastases of a 56 year old male melanoma patient. They 
have low invasive capacity and as mentioned before a rapid proliferation ability. These cells 
have a strong tendency to metastasize to the brain, lung, liver and bone (in vivo). The Melmet 
1 and Melmet 5 cells were transduced with a lentiviral vector, encoding CopGFP (a GFP 
variant) and Luciferase, resulting in the Melmet 1 pGF1 and Melmet 5 pGF1 cell lines.  
All cells were grown in ALT DMEM. The cells were kept in a standard tissue culture 
incubator at 37 °C with 100% humidity and 5 % CO2. The growth medium was exchanged 
twice a week.  
 
Figure. 2.1 – Figure showing morphological aspect of cell lines used in this work, scale bar 
50µm. 
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2.6) Monolayer viability assay 
 
The monolayer viability assay is based on the enzymatic reduction of resazurin by 
viable cells. Resazurin comes as a sodium salt (Sigma Aldrich, ST. Louis, MO, US), and was 
diluted to a stock solution of 1mg/mL in PBS (Sigma Aldrich). The stock solution was frozen 
at -20ºC until use. Before use, the stock solution was thawed and mixed with PBS to a 
working concentration of 0.1mg/mL. The amount of applied resazurin was 10% of the current 
volume of solution in the well or the dish.  
Three 96-well plates (Nunc, Thermo Scientific, USA) for each cell line were prepared 
with 8×103 cells/100µL into each well of the plate. After 24 hours of incubation to make sure 
the cells were attached to the surface, 100 µL of drug was added into each well, to obtain the 
following concentrations, 0.001 µM, 0.01 µM, 0.1 µM, 0.5 µM, 1 µM, 2.5 µM, 5 µM, 50 µM, 
100 µM or 500 µM. One column in each 96-well plates contained only cells and medium, 
without drug (negative control). Another column contained only medium, without adding 
cells or drug, and was used for calculation of background signal from the medium. As most of 
the drugs were dissolved in DMSO, a control of DMSO (0.01µM in ALT DMEM) was also 
prepared to ensure that this had no effect with cell viability, which was proved. After 72 hours 
of drug exposure, 20µL resazurin was added into all wells in the 96-well dish. Following 
incubation for 4 hours, the absorbance was measured at dual mode, at wavelengths of 560/590 
nm absorbance value with a scanning multiwell spectrophotometer (Victor 3 1420 multi-label 
counter, Perkin Elmer, Waltham, MA, USA) using WorkOut v2.0 software (Dazdag Solution 
Ltd. East Sussex, UK), which created an Excel spreadsheet with the measurement data, as the 
output of the experiment.  
All the results were transformed and prepared using the GraphPad Prism v6 software 
(GraphPad software, Inc, La Jolla, CA, USA). The data was normalized in Excel before being 
transferred to GraphPad Prism, where the data was transformed into a logarithmic form 
before fitted into a curve using a normalized response – variable slope logistic nonlinear 
regression analysis.  
This experiment was performed on all nine compounds. 
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2.7) DNA Cell Cycle Analysis 
 
 Treatment of cells started by seeding 1.5×105 cells into each well of a 6-well plate 
(Nunc, Thermo Scientific, USA). After 24 hours of incubation and making sure that the cells 
had attached to the surface, 100µM of either Methyldopa or Pentamidine was added to three 
of the wells. The other three wells were controls and only received ALT DMEM. Exposure to 
drug continued for 48 hrs before the samples were prepared for flow cytometric analysis. The 
experiments were performed for all four cell lines. 
The important point was to collect the cells and prepare the fixed samples while they 
were at approximately 70% confluency. It is important to avoid 100% confluency, as this will 
change the cell cycle towards more cells in the G1 phase. 
The fixation step began by removing the medium in each well, and adding 0.5mL 
trypsin. When the cells had detached from the surface, 1.0mL ALT DMEM was then added, 
the cell solution was transferred into sterile 15mL tubes, and centrifuged at 500rpm for 5 
minutes. The growth medium was then gently removed from the cell pellet, 100% ice cold 
EtOH was added, and the cells were re-suspended to obtain a homogeneous solution of cells. 
The cells were kept in the fridge (at 4ºC) until analysis.  
As final preparation before flow cytometry analysis, the fixed samples were collected 
from the fridge and centrifuged at 900rcf for 5 minutes, the EtOH was removed and then 
50µL 1mg/ml RNase (diluted in 1×PBS) and 150µL PI (Propidium Iodide) (50µg/ml) was 
added to the tubes. PI is fluorescent molecule that is used to stain the cells nuclei and has an 
excitation wavelength of 488 nm (39) and emits at a maximum wavelength of 617 nm. The 
samples were incubated at room temperature (RT) for 30 minutes in the dark to provide 
enough time for the RNase to dissolve free RNA in the cell solution (which otherwise would 
have been stained by PI, giving a false readout). The cell solution was transferred into a 2mL 
Eppendorf tube (Eppendorf AG, Hamburg, Germany) after passing through a cell strainer 
(Becton Dickinson Biosciences, MA, USA) and was mixed by a vortex mixer to make sure 
that the pellet was dissolved. All samples were analyzed using a BD AccuriC6 flow cytometer 
(Becton Dickinson Biosciences, NJ, USA). The fluorescence intensities were quantified by 
gating a two-parameter FL2-A and FL2-H cytogram to a one-parameter red fluorescence 
intensity plot. The data was further analyzed using Flowjo software (FlowJo, LLC, Ashland, 
OR, USA), to determine the % of cells in the different phases of the cell cycle. In this 
experiment, a peak area of FL2-H was recorded at 561 nm on a linear scale for the 
determination of cell cycle analysis, (39). 
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Figure. 2.2 – Schematic representation of flow cytometry data analysis: A representing raw flow 
cytometry data, B represents single cells within the circle, also called gate (the registered point outside 
the gate is either doublets or debris) and C cell cycle analysis (of the cells shown within the gate in Fig 
B). 
 
The data was analyzed using FlowJo software (FlowJo, LLC, Ashland, OR, USA). 
In FlowJo, after sorting the selected cell population into by adjusting the scale of the axis, 
viable cells were gated from the debris and other residue, see figure 2.4 –B and C. By using 
the provided software through univariate analysis of fractions of cells, cell cycle for the 
determined population was derived using DNA binding dye PI. The histogram shows G1, S 
and G2/M phases of the cell cycle under the categories of 2N, S, and 4N. It also revealed 
duration of each phase, and possible shift, figure 2.4 – C (40). 
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2.8) Apoptosis Assay 
 
First, 5×104 cells were seeded into each well of a 24-well plate (Nunc, Thermo 
Scientific, USA). After 12 hours of incubation, Methyldopa or Pentamidine were added into 
the wells at a concentration of 100mM. The cells were exposed to the drug for 72 hours. Cells 
exposed to 10mM H2O2 for 4 hours were used as positive controls. Thereafter, 80µL Rose 
Bengal (concentration 1mg/mL; Sigma Aldrich, MO, USA) was added into each well, and 
incubated for 30 minutes at 37ºC.  
 Cells were then collected and prepared for flow cytometric analysis. The top part of 
the medium in the wells was carefully collected using a 1mL pipette, and discarded. The 
remaining 1mL of medium, containing floating apoptotic cells, was collected in a 2mL 
eppendorf tube. 500 mL of PBS where then immediately added into the well to wash the 
plate, and the PBS was then transferred into the same eppendorf tube. In the next step, 500mL 
trypsin was added into the well and left in the CO2 incubator for a few minutes to detach the 
cells, and then transferred to the previous fractions. This procedure was repeated for all wells 
in the 24-well plate. All tubes were centrifuged (1×1000 rcf eppendorf centrifuge, 3 minutes 
at 4ºC). The supernatant was carefully removed, and the cells were washed twice, by re-
suspending the cell pellet in 900mL PBS, followed by centrifugation as described above. 
Finally, the supernatant was removed, and the cell pellet was re-suspended in 100mL PBS. 
The samples were then analyzed on AccuriC6 flow cytometer, in a two parameter FL2-H by 
FL2-A cytogram, and thereafter analyzed further using the FlowJo software, as previously 
described in Chapter 2.7. 
 
 
2.9) Soft Agar proliferation assay 
 
Agar is a gelatinous substance, which is difficult to work with, as it hardens quickly in 
room temperature. In this assay, it was necessary to mix the tumor cells with liquid agar, thus 
it was essential to keep the agar at 37 ºC during this procedure. This assay includes three 
different steps: first preparing base agar, then preparing soft agarose overlay, and finally 
adding the drug solution.  
1) Preparing base agar: For base agar preparation, 2.4% Difco Agar Noble (Becton 
Dickinson Biosciences, NJ, USA) was prepared by dissolving 0.48g Agar Noble in 20mL 
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autoclaved water (milliQ) in a glass bottle, warmed in a microwave and stirred until 
completely dissolved and homogeneous. Agar Noble solution and 60mL ALT DMEM were 
then warmed to 500C in a preheated water bath, and 3 parts of medium was mixed with 1 part 
of Agar Noble solution (3:1). 50µL of this mix was administered into each well in a 96-well 
plate and left at room temperature, to cool down.  
2) Soft agarose overlay: A low melting point agarose (Sigma-Aldrich) was then 
prepared and overlaid on top of the base agar solution. 0.48g of low melting point agarose 
was mixed with 20mL milliQ water in a glass bottle (2.4% solution), and microwaved until 
dissolved. The solution was then kept in preheated water bath together with ALT DMEM for 
approximately 10 minutes. The agarose solution was mixed with ALT DMEM (1 part agarose 
solution and 3 parts of ALT DMEM) and placed back into the water bath. At this point the 
temperature of the water bath was decreased to 400C. Meanwhile, the cell solutions were 
prepared at a concentration of 1.6×105 cells/mL in ALT DMEM and were kept in the 15mL 
tubes in the CO2 incubator. Two packages of filtered disposable pipette tips were placed in 
the CO2 incubator as well. One at a time, the tubes containing cell suspension were mixed 
with agarose overlay/ALT DMEM solution (1:1 mix). 50 µL of this mixture was 
administered, with preheated filtered pipette tips, on top of base agar in each well of the 96-
well plates. Afterwards, the plates were placed in a refrigerator for 30-35 minutes in order to 
prevent the cells from subsiding to the bottom of the soft agarose layer.  
3) Adding the drug solution. After 30 minutes the plates were fetched from the fridge 
and the wells were overlaid with ALT DMEM containing drugs, to final desired 
concentrations (0.001 µM, 0.01 µM, 0.1 µM, 0.5 µM, 1 µM, 2.5 µM, 5 µM, 50 µM, 100 µM 
or 500 µM).  
 Afterwards, the plates were left in the incubator for several days for the cells to form 
spheroids. The incubation time was different for the different cell lines. Melmet5 pGF1 had 
formed a lot of detectable spheroids after 7 days, while it took H1_DL2 and Melmet1 pGF1 
10 days to form spheroids. For the H3 cell line, it took 14 days to reach adequate numbers of 
spheroids. Resazurin was added to each plate and after 4 hours of incubation, each plate was 
analyzed in the spectrophotometer, followed by analysis in GraphPad Prism v6 as described 
in Section 2.5. This assay was repeated 3 times for each cell line and each drug. 
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2.10) Principles of Animal Handling 
First and most importantly of all who care for, use, or produce animals for research, 
testing, or teaching must assume responsibility for their well-being. The principles of animal 
laboratory science used to uphold the scientific rigor and integrity of biomedical research with 
laboratory animals are expected to be followed by all.  
Both researchers and institutions have affirmative duties of humane care and use that 
are supported by practical, ethical, and scientific principles. This system of self-regulation 
establishes a rigorous program of animal care and use and provides flexibility in fulfilling the 
responsibility to provide humane care. The specific scope and nature of this responsibility can 
vary based on the scientific discipline, nature of the animal use, and species involved, but 
because it affects animal care and use in every situation this responsibility requires that all 
that work with animals carry out purposeful analyses of proposed uses of laboratory animals.  
Following the European animal welfare (EWA) rights all animals must be treated humanely; 
• Freedom from hunger and thirst;  
• Freedom from discomfort; 
• Freedom from pain, injury and disease;  
• Freedom to express normal behavior;  
• Freedom from fear and distress. (EWA) 
Humane care means those actions taken to ensure that laboratory animals are treated 
according to high ethical and scientific standards. Implementation of a humane care program, 
and creation of a laboratory environment in which humane care and respect for animals are 
valued and encouraged.  
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Figure. 2.3 – Image of a nod/scid mouse used in in vivo experiments. 
 
When it comes to designing humane animal research studies, an accepted system is the 
implementation of the 3 R’s, Replacement, Refinement & Reduction.  
Replacement refers to methods that avoid using animals. The term includes absolute 
replacements (i.e., replacing animals with inanimate systems such as computer programs) as 
well as relative replacements (i.e., replacing animals such as vertebrates with cells).  
Refinement refers to modifications of husbandry or experimental procedures to 
enhance animal wellbeing and minimize or eliminate pain and distress.  
Reduction involves strategies for obtaining comparable levels of information from the 
use of fewer animals or for maximizing the information obtained from a given number of 
animals (without increasing pain or distress) so that in the long run fewer animals are needed 
to acquire the same scientific information (41). 
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2.11) MRI 
 
The superior imaging modality MRI, with its excellent tissue contrast, is a risk-free 
procedure for the patients because it does not use ionizing radiation.  
 The source of the MRI signal is based on the hydrogen nuclei or protons, which are 
abundantly present in tissue. Each proton is positively charged, and is also constantly 
spinning around its own axis. According to physics theory, a moving electrical charge of this 
kind generates a current, which in turn creates a magnetic field.  
 The orientations of all these protons in tissue are usually randomly directed, creating a 
net magnetic moment, which is zero. However, when a biological specimen is placed within 
the magnet of an MRI system, the protons will align either parallel or anti-parallel with the 
main magnet field, B0. The majority of protons will align parallel, as this requires the least 
energy. The difference between the number of protons aligned parallel and the number of 
protons aligned anti-parallel is usually very small. However, this difference increases with 
elevated magnetic field strength, and is the source for generating a signal, which in the end is 
reconstructed to become part of the MR image (42).  
 In order to detect a signal from the precessing protons, the protons need to be 
manipulated. Radiofrequency (RF) pulses are therefore switched on and off, knocking the 
protons out of the alignment with B0. The disturbance occurs when energy with the same 
frequency as the precession frequency is applied to the tissue, causing resonance. The net 
magnetic moment will as a consequence move out of alignment with B0, and the protons are 
moved into the transverse plane, or the x-y plane (42, 43).  
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Figure. 2.4 – Absorption of RF energy, starting with the net magnetization, using a RF pulse at 
Larmor frequency energy is absorbed by the protons causing net magnetizations to rotate from z plane 
to x – y plane, adapted from (43). 
 
 The use of an RF pulse will move some of the protons from the parallel to the anti-
parallel state, resulting in a reduction in overall longitudinal magnetism. Also the RF pulse 
makes the protons move in the same direction, or phase. The result is that a magnetization 
occurs in the transverse plane, moves at the Larmor frequency and thus generates an 
alternating voltage that can be detected in antennas or RF coils. The Larmor frequency is the 
sum magnetic field from these protons, which is now regarded a single vector M0, rotates 
around B0 with a precession frequency determined by the magnetic field. This signal is used 
in the formation of an MRI signal. When the RF pulse is turned off the protons will start to 
move out of phase and lose energy, termed «proton relaxation».  
This takes place in two ways; transverse magnetism is referred to as T2 or spin-spin 
relaxation, and longitudinal magnetism returns to the initial situation called T1 or spin-lattice 
relaxation. The speed at which T1 relaxation occurs is dependent on the properties of the 
surroundings. Therefore, different tissues or arrangements with hydrogen to other substances 
will produce different T1 relaxation times. The time constant T1 is the time it takes until 
longitudinal magnetism is regained to 63 % of its final value (Fig. a). T2 relaxation describes 
loss of in-phase protons due to in homogeneities within the local tissue and within B0. The 
time constant T2 describes the time it takes before transverse magnetism is reduced to 37 % 
(Fig. b) (42, 43).  
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Fig. 2.5 – Representation of T1 and T2 curves. a) T1 characteristic of tissue, consisting of the time 
it takes for longitudinal magnetization to recover to 63%. b) T2 characteristic of tissue, consisting of 
the time it takes for transversal magnetization to decrease to 37%. Adapted from (43). 
 
MRI studies were performed using a Bruker Biospec 7 Tesla (7 T) small animal 
scanner (Bruker BioSpin MRI, Ettlingen, Germany) equipped with a mouse head 
transmit/receive coil for transmit and a four channel mouse brain phased array for receive. 
Images were acquired using ParaVision 5.1 (Bruker BioSpin MRI). MRI was used to study 
tumor burden with and without drug in a nod/scid mouse after administration of the Omniscan 
contrast (GE Healthcare, Fairfield, CT, USA) as commonly used in the clinic.  
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3) Results 	  
 
Prior to my arrival, animal models and drug selection had been established, with 
cMAP results represented in subsection 3.1. My task consisted of a preliminary in vitro drug 
screening with the application of possible candidates in in vivo trials, of the remaining 9 
candidates. 
 
3.1) cMAP and Drug Selection 
 
After intracardiac injections, tumor burden was seen mainly in the animal brains, and 
to some extent in bone, adrenals and ovaries (Figs 3.1A, 3.1 B). Principal component analysis 
showed distinct clustering of the gene data obtained from the different organs (Fig 3.1 C). A 
bioinformatics analysis was performed, comparing differentially expressed genes in the brain 
metastatic cells, with gene expression in the metastatic cells from adrenals, bone and ovaries. 
From the analysis we could determine a list of 108 candidate genes (54 up, 54 down; Fig 3.1 
D), potentially important in metastasis to the brain. This gene list was compared to gene 
profiles published online (Connectivity Map or cMap, Broad Institute, Boston, MA). In cMap, 
thousands of commonly used compounds and drugs have been tested on several different 
cancer cell lines, and gene profiles before and after treatment have been determined and 
published online (Fig 3.1 E). We found that 20 drugs published in cMap resulted in the exact 
opposite gene profile, compared to our gene profile. The top ten drugs were tested in Prof 
Thorsens lab prior to my arrival (Fig 3.1 F), if any of them showed efficiency in vitro, they 
continued to study in vivo. They found that β-sitosterol effectively inhibited brain 
metastatic tumor cell growth in vitro and in vivo.  
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Figure. 3.1 Tissue sample generation, expression profiling, and Connectivity Map analysis. A. 
BLI at 5 weeks post injection of 5*105 H1DL2 cells. B. Detailed mapping of organ involvement by ex 
vivo BLI. C. Principal components analysis of all replicates (brain-blue, ovaries-green, adrenals-red, 
bone-purple). D. The brain metastasis gene signature with the left two panels showing 54 genes that 
were upregulated in brain metastases and the right two panels showing 54 genes that were 
downregulated in brain metastases. E. Query results from the cMap database using the 108-gene 
signature. A score of <0 to –1 means net reversal of the signature (negative correlation) and a score of 
>0 to +1 means net induction of the signature (positive correlation). F. Top 10 compounds from the 
Connectivity Map (cMap) analysis with the potential to induce the opposite transcriptional response to 
the brain metastasis signature (“anti brain metastasis signature”). Chemical abstracts service (CAS) 
registry numbers, reported dose tested, cMap score, and molecular weight (MW) are provided.  
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3.2) In Vitro Studies 
3.2.1) Monolayer Viability Assay 
 
The monolayer viability assay was used to study cell viability based on Resazurin 
reduction as described in chapter 1.7.1. The experiments were done for all the four cell lines, 
using the same drug concentrations and the same observation time. 
 
 
 	  Figure 3.2 - Monolayer proliferation assay for Decamethonium Bromide, Fluticasone, Gabexate 
and Sulphapyridine in all cell lines.  The cells were treated with different concentrations of the drugs 
to study the possible inhibitory effect on the proliferation capacity of these tumor cells. The 
experiment was replicated 3 times under the same conditions.  
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As shown in figure 3.1, the drug-response plots used to determine the inhibitory 
effects of Decamethonium Bromide, Fluticasone, Gabexate and Sulphapyridine on the 
viability of the cell lines, showed almost linear graphs, regardless of drug concentration. In 
other words, these three drugs did not affect cell viability. 
 
 
Figure 3.3 - Monolayer Viability assay for Lymecycline, Methyldopa, Lanatoside C, 
Trichostatin A and Pentamidine in all cell lines. The cells were treated with different concentrations 
of the drugs to study the possible inhibitory effect on the proliferation capacity of these tumor cells. 
Experiment was replicated 3 times under the same conditions.  
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As shown in figure 3.2, the drug-response plots, used to determine the inhibitory 
effects of all represented drugs on the viability of the cell lines, ,showed a sigmoidal shape.  
The percentage of relative viability (Y-axis) was plotted as a function of the logarithmic drug 
concentration (X-axis) for all four cell lines. The required dose of Lymecycline and 
Methyldopa for 50% inhibition (IC50) of the cell viability was in the 10-5 range, followed by 
Pentamidine with 10-6, the Trichostatin A and Lanatoside C with 10-7. A table containing all 
IC50 values is found in chapter 3.3. Drug doses below the IC50 value did not have a statistical 
significant inhibitory effect. In our experiments, a sufficient range of drug concentrations 
were chosen to ensure that there were enough points below and above the IC50 dose, thereby 
ensuring that a proper curve fit could be made. 
The relatively flat slope of a dose response curves below the IC50 dose suggest that the 
effect on viability in this dose range was minimal.  
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3.2.2) Soft Agar proliferation 
 
 The soft agar assay was employed to study spheroid development of melanoma brain 
cells in presence and absence of treatment. Cells were cultured in soft agar, and developed 
into spheroids during a time period of up to 14 days.   
 
 
Figure 3.4 – Soft agar proliferation assay for Lymecycline, Methyldopa, Lanatoside C, 
Trichostatin A and Pentamidine. The cells were treated with different concentrations of the drugs to 
study the possible inhibitory effect on the proliferation capacity of these tumor cells. Experiment was 
replicated 3 times under the same conditions. Curve fits not possible in all samples. 
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Only the drugs that showed decrease in cellular viability in the Monolayer 
proliferation assay were screened utilizing this assay: Lymecycline, Methyldopa, Lanatoside 
C, Trichostatin A and Pentamidine. 
All five drugs showed an inhibitory effect on tumor cells grown in the 3D agar assay. 
The survival curves for Lymecycline cells, first row in figure 3.4, showed that the required 
doses for 50% maximal inhibitory (IC50) differed between all cell lines, ranging between 10-
5M and 10-7M. When using Methyldopa (second row in figure 3.4), the required doses for 
50% maximal inhibitory (IC50) ranged between 10-5M and 10-10M. The results showed that 
this drug is very effective on the H3 cell line.  
Both Lanatoside C and Trichostatin A, row three and four respectively in figure 3.4 
showed that the required doses for 50% maximal inhibitory (IC50) was constant between all 
cell lines requiring a concentration in the 10-7M region, to negatively affect the viability. 
Finally Pentamidine (fifth row of figure 3.4), showed that the required doses for 50% 
maximal inhibitory (IC50) was constant for 3 cell lines, H1_DL2, Melmet1 and Melmet 5 
requiring a concentration in the 10-6M region. The IC50 dose for the H3 cell line was 10-5 M. 
When concentrations higher than the IC50 doses were administered to the cells, this 
affected the cells considerably, as they showed lower capacity to reduce Resazurin to 
resorufin, indicating decreased number of viable cells. A table containing all IC50 values is 
shown in chapter 3.3. 
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3.2.3) Summary of all IC50 Results 
 
Table 3.5 shows all the IC50 doses obtained for the monolayer assay and the soft agar 
assay. Each result is mean value ± SD of three experiments. The results show that Lanatoside 
C and Trichostatin A were the most effective drugs, followed by Pentamidine. Reliable values 
for the IC50 doses could not be obtained for Decamethonium Bromide, Sulphapyridine, 
Fluticasone and Gabexate, as these drugs affected cell viability only minimally. 
 
Table 3.1 – Table containing IC50 values for all In vitro studies. 
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3.2.4 DNA Cell Cycle Analysis 
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Figure 3.5 - Cell cycle analysis of H1_DL2, H3, Melmet1 pGF1, and Melmet5 pGF1 by flow 
cytometry. Cell cycle phases in the histograms represented above are color coordinated, where the 
purple color is the estimated G1 phase, the green color is the estimated S phase, and the red color is 
the estimated G2 phase. We considered <2N along with 2N as G1 phase, and 4N along with >4N as 
G2/M phase. Histogram presents axis of FL2-A vs. Count, that represents number of events able to 
pass FL2 filter, which is a PMT (photomultiplier tube) detector that allows wavelengths between 565 
and 605nm to pass through. 
 
 Flow cytometry was employed to study the effects of drug on the cell cycle of the 
different cell lines. Triple experiments were performed on all cell lines, using 100mM of 
Methyldopa or Pentamidine. Untreated cells were used as negative controls. We did not 
perform flow cytometry using Lymecycline or Lanatoside C, as these drugs are too large to 
cross an intact blood-brain barrier, and therefore were excluded from further in vivo 
experiments. Trichostatin A was also excluded from this analysis, as in vivo experiments 
(which were done before we did the DNA analysis) showed no drug effects on the brain 
tumors in animals. 
 When H1_DL2 cells (figure 3.6 first row) were treated with Methyldopa we noticed a 
broadened G2/M phase whereas when treated with Pentamidine the G1 phase was broadened 
and S phase slightly arrested. With the H3 cells (figure 3.6 second row) there was a 
significant increase in G2/M phase with both drugs with the addition of a broadened S phase 
with Pentamidine. Both drugs had a severe effect on Melmet 1 (Figure 3.6 third row) with an 
arrest of the G1 and S phase and a significant increase in the G2/M phase once treated with 
Methyldopa. Whilst when treated with Pentamidine we observe a broadened G2/M phase and 
an arrested G1 phase. Melmet 5 (figure 3.6 forth row) once treated with Methyldopa it was 
clear to see that G1 and S phase broadened with an arrest in the G2/M Phase. Meanwhile when 
treated with Pentamidine no significant phase shift was verified apart from a slightly higher 
accumulation in the G2/M region.  
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Table 3.6 shows all the values in percentage of each cell cycle phase, for each cell line 
and the two drugs used. Each result is mean value ± SD of three experiments. The results as 
explained above clearly show phase shift within all treatments but, statistically the most 
relevant shift if found when H1_DL2 is treated with Pentamidine. Here we can evidently see 
a reduction in the G2/M phase. 
 
Table 3.2 – Statistical information relative to cell cycle analysis, mean values ± SD of the 
whole experiment. ns = not significant (P > 0.05); * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 
0.001; **** = P ≤ 0.0001. 
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3.2.5) Apoptosis assay 
 
A colorimetric method was used to determine potential changes in apoptosis for the 
four cell lines after treatment with Pentamidine and Methyldopa. We did not perform the 
apoptosis assay using Lymecycline, Lanatoside C and Trichostatin A, for the same reasons as 
explained in Section 3.3  
 
 
 
Figure 3.6 – Apoptosis assay on H1_DL2 human melanoma metastasis cell line. Represented 
above (first row) is a linear forward-scatter vs. side-scatter plot (FSC-H vs. SSC-H). FSC gives us 
information relative to the size of healthy/dead cell whilst, SSC informs us about cell fluorescence and 
granularity. It can be inferred that a rough cell such as a cell undergoing apoptosis would have high 
side scatter signals. These cytograms display both cells and cell debris, cell of interest are gated 
excluding debris. The second row shows FL3-A vs. FSC-H cytograms (FL3 channel used to detect 
rose bengal fluorescence); show gated cells from row above. We can clearly see two cell populations, 
as distinguished by the vertical axes. The upper populations are the apoptotic cells, since they express 
more color. Apoptotic cells were then gated giving us a total value in percentage. 
 
 
 
For untreated H1_DL2 cells, 7.3% of the cells were apoptotic. When treated with 100 
µM Methyldopa, around 98% of all cells were apoptotic, while around 99% of the cells were 
apoptotic after treatment with 100mM Pentamidine (Figure 3.7, Table 3.11). 
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Figure 3.7 – Apoptosis assay on H3 human melanoma metastasis cell line. Represented above 
(first row) is a linear forward-scatter vs. side-scatter plot (FSC-H vs. SSC-H). FSC gives us 
information relative to the size of healthy/dead cell whilst, SSC informs us about cell fluorescence and 
granularity. It can be inferred that a rough cell such as a cell undergoing apoptosis would have high 
side scatter signals. These cytograms display both cells and cell debris, cell of interest are gated 
excluding debris. The second row shows FL3-A vs. FSC-H cytograms (FL3 channel used to detect 
rose bengal fluorescence); show gated cells from row above. We can clearly see two cell populations, 
as distinguished by the vertical axes. The upper populations are the apoptotic cells, since they express 
more color. Apoptotic cells were then gated giving us a total value in percentage. 
 
 
For the H3 cell line, untreated cell populations contained 8.5% apoptotic cells, and in 
cells treated with Pentamidine around 99% of the cells were apoptotic. After Methyldopa 
treatment, approximately 95% were apoptotic (Figure 3.8, Table 3.11). 
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Figure 3.8 – Apoptosis assay Melmet1_pGF1 human melanoma metastasis cell line. Represented 
above (first row) is a linear forward-scatter vs. side-scatter plot (FSC-H vs. SSC-H). FSC gives us 
information relative to the size of healthy/dead cell whilst, SSC informs us about cell fluorescence and 
granularity. It can be inferred that a rough cell such as a cell undergoing apoptosis would have high 
side scatter signals. These cytograms display both cells and cell debris, cell of interest are gated 
excluding debris. The second row shows FL3-A vs. FSC-H cytograms (FL3 channel used to detect 
rose bengal fluorescence); show gated cells from row above. We can clearly see two cell populations, 
as distinguished by the vertical axes. The upper populations are the apoptotic cells, since they express 
more color. Apoptotic cells were then gated giving us a total value in percentage. 
 
 
For the untreated Melmet 1 cell line, approximately 6% were apoptotic. After 
treatment with Pentamidine around 98% of the cells showed apoptosis. Around 97% of the 
cells were apoptotic after treatment with Methyldopa (Figure 3.9, Table 3.11). 
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Figure 3.9 – Apoptosis assay on Melmet5_pGF1 human melanoma metastasis cell line. 
Represented above (first row) are linear forward-scatter vs. side-scatter plots (FSC-H vs. SSC-H). FSC 
gives us information relative to the size of healthy/dead cell whilst, SSC informs us about cell 
fluorescence and granularity. It can be inferred that a rough cell such as a cell undergoing apoptosis 
would have high side scatter signals. These cytograms show both cells and cell debris, cell of interest 
are gated excluding debris. The second row shows FL3-A vs. FSC-H cytograms (FL3 channel used to 
detect rose bengal fluorescence); show gated cells from row above. We can clearly see two cell 
populations, as distinguished by the vertical axes. The upper populations are the apoptotic cells, since 
they express more color. Apoptotic cells were then gated giving us a total value in percentage. 
 
 
Untreated Melmet 5 cells had approximately 2.5 ± 0.6 % apoptotic cells, after 
Pentamidine treatment around 98.6% of the cells were apoptotic, and after Methyldopa 
treatment approximately 99.5% were apoptotic (Figure 3.10, Table 3.11).  
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Table. 3.3 – Percentage of apoptotic cells for untreated cells, and cells treated with 100mM 
Pentamidine or 100mM Methyldopa. As positive controls, cells were treated with 10mM H2O2. The 
results shown are mean values of 3 experiments ± standard deviation. ns = not significant (P > 0.05); * 
= P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001. 
 
 
Cell 
Line 
Untreated [%] Pentamidine [%] Methyldopa [%] 
Positive Control 
[%] 
H1_DL2 7.4 ± 1.8 99.1 ± 0.3**** 97.8 ± 0.5**** 99.7 ± 0.5**** 
H3 8.2 ± 0.2 95.5 ± 0.6**** 94.5 ± 0.6**** 99.9 ± 0.1**** 
Melmet 1 5.5 ± 2.7 98.1 ± 0.8**** 97.1 ± 2.3**** 98.9 ± 0.1**** 
Melmet 5 2.5 ± 0.6 98.6 ± 0.2**** 99.5 ± 0.2**** 99.7 ± 0.3**** 
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3.3) In Vivo Studies 
3.3.1) Experimental Layout 
 
Three drugs were tested In Vivo, (Trichostatin A, Methyldopa and Pentamidine). Drug 
selection was based on In Vitro results and molecular weight to have a higher change of 
crossing the BBB. 
 
 
3.3.2) In vivo Trichostatin A (TSA) treatment 
 
The first animal experiment was performed to determine the potential in vivo effects 
of Trichostatin A.  The National Animal Research Authority approved all animal procedures. 
Twelve weeks old female nod/scid mice were injected with 1·106 H1_DL2 cells in the left 
cardiac ventricle.  
Treatment then began the following day; animals were subdivided into 2 groups, one 
control group (no treatment, n = 8 animals), and one treatment group (1 mg/kg TSA, n = 8 
animals). Treatment groups received intraperitoneal injections three times a week of the drug 
at a dosage of 1mg/kg. The animals were then kept in the animal facility under standard 
conditions; being fed a standard pellet diet and provided water ad libitum.  
All groups were monitored daily and weighed 3 times per week to ensure the animals 
wellbeing, and to terminate the experiment within parameters of that which are humane 
(humane endpoints). 
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Figure. 3.10 – Illustration of intercardiac injection and interperitoneal treatment. Injection of 
tumor cells into the left cardiac ventricle of nod/scid mice (a). Ultrasound guided injection to left 
cardiac ventricle (b;c). Drug treatment consisting of intraperitoneal injections (d). 
 
3.3.3) In vivo Pentamidine and Methyldopa treatment 
 
In a second animal experiment, the two remaining drug candidates, as determined by 
the in vitro screening (Methyldopa and Pentamidine) were tested for in vivo efficacy. The 
National Animal Research Authority approved all animal procedures. Twelve weeks old 
female nod/scid mice were injected with 5·105 H1_DL2 cells in the left cardiac ventricle. 
Treatment then began the following day; the animals were subdivided in 3 separate groups 
with each group containing 4 animals. The first group was a control group, which received no 
treatment. The second group received intraperitoneal injections three times a week of 
Methyldopa dissolved in PBS at a dose of 20mg/kg. The third group received intraperitoneal 
injections 5 times a week of Pentamidine dissolved in PBS at a dose of 10mg/kg. The animals 
were then kept in the animal facility under standard conditions; being fed a standard pellet 
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diet and provided water ad libitum. All groups were monitored daily and weighed 3 times a 
week to ensure the animals wellbeing, and to terminate the experiment within parameters of 
which is humane (humane endpoints).  
 
3.3.4) In vivo TSA 
 
                                     Control                                Treatment 
 
Figure. 3.11 - Representative MRI Scans of mice brains during TSA In vivo treatment over the 
period of the experiment. T1 scans after administering contrast were used to qualify tumor burden 
and volume. In these images its clear to see tumor establishment and progression throughout the 
experiment. Lighter white areas are tumors, which are emphasized due to uptake of the contrast agent 
Images a, c and e – Control animals over a period of 4, 6 and 8 weeks respectively. Images b, d and f 
– Animals treated with 1 mg/kg of TSA over a period of 4, 6 and 8 weeks respectively. As can be 
visualized tumor burden increases with the passing of time in both control and treatment mice, 
although this is much more apparent when treated with TSA. 
Week	  4	  
Week	  6	  
Week	  8	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Figure. 3.12 – Graph representing tumor burden and volume during treatment at week 8. A) 
Tumor volume in untreated and treated animals. B) Tumor burden in untreated and treated animals. As 
is visualized both tumor volume and burden has a tendency to be increased in treated animals although 
not statistically significant. 
 
 
Figure. 3.13 – Graphic illustrating animal survival thought the course of the experiment. Both 
control and treatment animals had a very similar survival rate, no increase when treated with TSA. 
  
 
 
 
 
A) B) 
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Figure. 3.14 – Graphic illustrating animal weights thought the course of the experiment. Graph 
shows animal weights declining throughout the experiment, with both groups weight declining at a 
similar ration, TSA group maintained relatively good weight until the end of the experiment. 
 
In vivo experiments using TSA proved inefficient, tumor burden was maintained very 
similar to control animals.  Mice treated with TSA had larger tumors in comparison to control 
animals and this is very clear in (Figure 3.12). Treated animals did not loose as much weight 
as control animals, but nothing significant and all in all animal survival was not affected. 
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3.3.5) In vivo Pentamidine/Methyldopa 
 
                    Control                    Methyldopa                 Pentamidine 
 
Figure. 3.15 - Representative MRI Scans of mice brains during Methyldopa/Pentamidine in vivo 
treatment over the period of the experiment. T1 scans after administering contrast were used to 
qualify tumor burden and volume. In these images its clear to see tumor establishment and progression 
throughout the experiment. Lighter white areas are tumors, which are emphasized due to uptake of the 
contrast agent. . Images b and f – Animals treated with 20 mg/kg of Methyldopa over a period of 4 to 
6 weeks respectively. Images c and g – Animals treated with 10 mg/kg of Pentamidine over a period 
of 4 to 6 weeks respectively. As can be visualized tumor burden increases with the passing of time in 
both control and treated mice. 
 
 
Week	  4	  
Week	  6	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Figure. 3.16 – Graph representing tumor burden and volume during treatment at week 4. A) 
Number of tumors in untreated and treated animals. B) Tumor volume in untreated and treated 
animals. Number of tumors is greater in control animals followed by Pentamidine, with methyldopa 
showing promising results. The same is verified with tumor volume. 
 
 
 
 
 
 
 
Figure. 3.17 – Graph representing tumor burden and volume during treatment at week 6. A) 
Tumor burden in untreated and treated animals. B) Tumor volume in untreated and treated animals. 
The results here show that at week 6 none of the drugs had promising effects on tumor burden and 
volume.  
 
 
 
A) B) 
A) B) 
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Figure. 3.18 – Graphic illustrating animal survival through the course of the experiment. As seen 
in the graph, 1 animal of the Pentamidine treatment group was euthanized around day 41, with all the 
remaining animals euthanized at day 47 terminating the experiment, to ensure wellbeing and minimize 
animal suffering (humane endpoints).  
 
 
 
Figure. 3.19 – Graphic illustrating animal weights throughout the course of the experiment.  
Graph shows animal weights declining throughout the experiment, with a gain of weight in 
methyldopa treated animals around week 4. 
 
 
In Vivo experiments using Pentamidine proved inefficient, tumor burden maintained 
very similar to control animals.  Mice treated with this drug had similar results as control 
animals throughout the experiment (week 4 and 6) and this is clear in figures represented 
above. Treated animals lost a lot of weight in the beginning of the experiment but other 
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groups caught up. This group’s survival was worse than the control and methyldopa group 
with the loss of one animal around day 41. 
 
In vivo experiments using Methyldopa proved efficient, in an early stage. A transient 
effect was verified around week 4, with less and smaller tumors in comparison to the other 
test groups (Figure – 3.16 and 3.17). Mice around this time seemed healthier in comparison to 
others with gained weight. Although reaching week 6 both tumor burden and volume 
increased significantly even more so than the control group. Survival was the same as control 
animals. 
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3.3.6) MRI Protocol Optimization 
 
 
Figure 3.20 – Representative MRI Scans showing progress of MRI protocol optimization. A – 
Axial T1 weighted scan with 1mm thickness. B – Coronal T1 weighted scan with contrast with 0.5mm 
thickness. C – Coronal T2 weighted scan with contrast, with black spot (Contrast leaking from blood 
vessels; white arrow). 
 
During the pilot study (TSA study) it was often difficult to see the tumors on T1 weighted 
images in axial sections with a slice thickness of 1 mm (Fig A). Unsatisfied with the results 
we wanted to test coronal slice selection instead (Fig B). Further, to improve resolution, we 
used 0.5mm slice thickness instead and increased Number of Averages. By doing 
coronal+0.5mm it was a lot easier to see the tumors, compared to axial. Further, we 
performed a T2 weighted scan after administering contrast and then the T1 sequence. The 
reason is: If the blood brain barrier is leaky, Omniscan will leak out from the blood vessels 
and accumulate in the tumor tissue. When a T2w scan is performed, the Omniscan contrast 
will then affect the contrast in this area. Omniscan will result in larger inhomogeneities in the 
tumor tissue, and transverse relaxation is lost much quicker than without Omniscan (so the T1 
contrast agent has in fact a T2 effect as well). As a result the leaky tumors will appear as 
hypointensive (i.e. black) spots (Fig. C). 
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4) Discussion/Conclusion 
 
In general, 40-60% of all cancer patients develop brain metastases during the 
progression of malignancy, of which a fifth are diagnosed with secondary brain tumors before 
the primary site neoplasm is located or identified (44). The current treatments are not 
effective, so it is of uttermost importance to find alternative treatment strategies. 
Chemotherapy alone is generally ineffective for the treatment of melanoma CNS metastases. 
Failure of systemic treatment for brain metastases in the past has been blamed on the inability 
of most experimental agents to pass the blood–brain barrier in addition to the low activity of 
these agents against melanoma (18, 45).  An alternative would be to investigate and study 
other compounds, but the development of a new drug is risky and an expensive process (46). 
It takes on average 12 years and over US$350 million to get a new drug from the laboratory 
onto the pharmacy shelf. Once a company develops a drug, it undergoes around three and a 
half years of laboratory testing, before an application is made to the U.S. Food and Drug 
Administration (FDA) to begin testing the drug in humans. Only one in 1000 of the 
compounds that enter laboratory testing will ever make it to human testing. (47). 
A different approach to this issue is the main objective of this work, which is to re-
purpose drugs, which are already FDA approved, to cut the waiting period. 
In a previous work, a list of genes potentially important in metastasis to the brain was 
identified. Through the capabilities of cMAP, a list of 20 compounds were published and 
resulted in the exact opposite gene profile. Ten of these compounds had already been tested; 
the objective of this work was to screen the remaining (chapter 2.1). 
In this project a variety of in vitro screening assays were performed to study the effect of the 
selected drugs on four human metastatic melanoma cell lines. The most promising of these 
drugs were then tested in an in vivo model system. 
 All drugs were subjected to Monolayer Proliferation assay on all four human 
melanoma metastatic cell lines; in this assay 4 drugs were excluded (Sulphapyridine, 
Decamethonium Bromide, Fluticasone and Gabexate). These drugs showed no potential 
inhibition on cell proliferation therefore were not subjected to Soft Agar Assay. The 
promising drugs were Trichostatin A, Lanatoside C, Pentamidine, Methyldopa and 
Lymecycline. Trichostatin A is a potent histone deacetylase inhibitor that has proven effective 
against breast cancer both in vitro and in vivo, resulting in cell apoptosis (48, 49). Lanatoside 
C has been proven to upregulate the death receptor 5 inducing apoptosis through a caspase 
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independent cell death pathway (50). Pentamidine inhibits PRL family of oncogenic 
phosphatases, which potentially have a pathogenic role in human malignancies. It was tested 
on human WM9 melanoma cells and growth inhibition and necrosis was observed (51). 
Lymecycline is a tetracycline antibiotic that inhibits cell growth by inhibiting translation. This 
results in inhibition of protein synthesis and hence cell growth (52). No information relative 
to pathway of action of Methyldopa has been specified, but it is a very cytotoxic drug, and 
concentration administered and direct cell contact is probably the reason cell growth was 
affected (53).  
 
Soft Agar analysis with the 5 effective drugs from the Monolayer Proliferation assay also 
showed promising inhibitional properties on all cell lines. The most promising drugs 
following these experiments were Trichostatin A and Lanatoside C, having consistent results 
in all cell lines with IC50 values in the (10-7) range.  
Due to the limited period of stay at UoB, Norway (Erasmus Period) and after careful 
deliberation it was decided to use one of these drugs in an in vivo pilot study. Trichostatin A 
was the selected drug, due to results in preliminary in vitro screening and because of its 
molecular weight of 302,37 Da, ideal to cross the BBB see chapter 1.6. Trichostatin A is an 
antifungal antibiotic that selectively inhibits mammalian histone deacetylases class I and II, 
and it is a potential chemotherapeutic agent (48) which has never been tested on melanoma 
brain metastasis. In vivo results using this drug differed from what was expected after in vitro 
screening. MRI scans were performed on weeks 4, 6 and 8 of the experiment, and it was 
clearly observed that animals treated with TSA had tumors higher in number and volume 
compared to untreated animals (figure. – 3.11). Weekly weighing was performed to certify 
the animal’s wellbeing, treated animals kept their weight more than control animals.   
 Due to the limitations of the BBB, Lymecycline and Lanatoside C were excluded from 
the following experiments (Cell cycle analysis and apoptosis) and therefore the remaining 
drugs to be tested were Methyldopa and Pentamidine. Cell cycle Analysis was performed of 
all cell lines with a concentration of 100mM of each drug and a respective positive and 
negative control. Results where not coherent between cell lines but shifts were observed in all 
cases. In general when treated with Methyldopa we notice a broadened G2/M phase with the 
exception of Melmet 5 where we verified a broadened G1 and S phase. The G2/M DNA 
damage checkpoint consists of an arrest of the cell in G2 just before mitotic entry in response 
to genotoxic stress (54). The arrest caused by Methyldopa exposure, could be associated in 
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part, with inhibited activity of p34(cdc2) kinase and reduced accumulation of p34 (cdc2) and 
cyclin B1 proteins (55).  In cancer, G1 phase is affected, generally because gene regulatory 
proteins of the E2F family have become unrestrained and G1/S cyclin gene expression is 
increased, leading to uncontrolled cell-cycle entry (56). Methyldopa may be preventing cells 
from entering G1 phase, therefore stopping Melmet 5 cells from dividing and spreading. 
When treating H1_DL2 and Melmet 1 cells with Pentamidine, we verified a shift in G1 phase; 
there was an accumulation of cells in the first and a reduction in the latter. In H1_DL2 it 
seems that cells cannot transition into the next phase and in Melmet 1 they cannot enter G1 
phase. H3 and Melmet 5 have a rise in the G2/M phase, same as described above. So we can 
conclude that the drugs did affect the cell cycle at some point.  
Both drugs were subjected to an apoptosis assay, to quantify apoptotic content through the aid 
of flow cytometry. Very coherent and statistically relevant data (P ≤ 0.0001) resulted from 
cell exposure to drug concentration of 100mM. Cell apoptosis was in the range of 95-99%. A 
possible explanation could be p38 activation as well as ERK and Akt inactivation, which will 
result in apoptosis (57). We did not have time to perform Western Blot in order to confirm 
this. 
Up to now Methyldopa and Pentamidine proved to be very strong candidates so they were 
subjected to an in vivo study as described above, see 3.3.3.  MRI scans were performed on 
week 4 and 6 to verify and quantify tumor burden and volume.  Results with Pentamidine 
were very similar to untreated animals, and no tumor effects could be seen. In contrast, when 
treated with Methyldopa, on week 4 the results looked promising with a reduction in tumor 
number and volume (Fig. - 3.16), which was also visible in the animals weights (Fig. – 3.19), 
and around day 28 animals gained weight and had a healthier appearance. Unfortunately the 
animal’s heath rapidly depleted around week 6, where tumor burden and volume grew to 
same levels observed both in the untreated mice and in the mice treated with Pentamidine. 
Nonetheless, Methyldopa had a transient effect around week 4, which could mean that this 
drug should not be discarded as a possible form of treatment. This was not the case for week 
6, but by optimizing protocol and maybe combining it with other drugs, it may still have a 
value. Professor Thorsen’s group has showed treatment effects using β-sitosterol, and 
combined treatment with Methyldopa should be an aim for further studies. Therefore, further 
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studies still need to be performed, in the hope that this drug could also be trialed, as 
preventive form of treatment to melanoma brain metastasis. 
It is also possible that results could be different for all drugs verified in vivo if other 
concentrations and drug delivery methods were tested. TSA has been tested in vivo before and 
administration was performed subcutaneously. (48). 
In addition, because MRI protocols were optimized, it is now easier to detect the tumors, 
especially the smaller ones. In addition it is also possible to verify whether the tumors are 
leaky or not. This could be used in future animal studies, to see whether leakiness changes as 
a function of treatment. 
 
5) Future aspects 
 
Further studies should be performed to verify the applicability of Methyldopa in the treatment 
of melanoma metastasis. In vivo studies should be performed experimenting with different 
doses and forms of administration. Furthermore, results from this work suggest that 
Methyldopa could be applied as a preventive form of treatment, and this should also be tested 
by starting treatment for instance one week before tumor cell injections.  
Lanatoside C showed very good results in vitro and should not be discarded; its main obstacle 
is the BBB. Once there is a way to open and facilitate the passage through the BBB, this drug 
should be an immediate candidate. Work is now ongoing in Thorsens lab, to transiently open 
the BBB by using a novel K16ApoE peptide (58). The group is able to effectively 
permeabilise the BBB, as shown by MRI, and future studies will aim at delivering therapeutic 
compounds that are not able to penetrate through intact brain vessels. 
Additionally all these proposed studies will require in vivo studies, and utilizing the optimized 
MRI protocol will be of great benefit, since improved resolution and the ability to study 
tumor leakiness will add further value to the studies. 
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